SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DYGN - Dynagen

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Timewalker who wrote (374)8/24/1998 10:54:00 AM
From: WTT2  Read Replies (1) of 444
 
Time, I dont think WARNER LAMBERT would waste there time w/ DYGN...they certainly have numerous other options!!!!
DynaGen Announces a Multi-Year Supply Agreement With Warner-Lambert

CAMBRIDGE, Mass.--(BW HealthWire)--Aug. 24, 1998--DynaGen Inc. (NASDAQ:DYGN)(BSE:DYG) today announced that its wholly owned subsidiary, Able Laboratories Inc., has signed a multi-year supply agreement with Warner-Lambert Co., of Morris Plains, N.J., to manufacture a product for their international markets.

Able manufactures oral solid dosage products, including generic versions of the brand Pyridium as well as suppositories at its South Plainfield, N.J. facility. The company continues development of generic and specialty pharmaceutical products for use in women's health care and the gastrointestinal treatment markets, while continuing to secure private labeling and contract manufacturing agreements with multi-national pharmaceutical companies. "Able will continue to secure alliances with multi-national pharmaceutical companies and for positioning ourselves as an upcoming significant player in the branded and generic pharmaceutical markets," said Indu A. Muni, Ph.D., president and chief executive officer of DynaGen.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext